Original-Research: Clinuvel Pharmaceuticals Ltd - von Sphene Capital GmbH

Einstufung von Sphene Capital GmbH zu Clinuvel Pharmaceuticals Ltd

Unternehmen: Clinuvel Pharmaceuticals Ltd
ISIN: AU000000CUV3

Anlass der Studie: Initiation of Coverage
Empfehlung: Buy
seit: 30.01.2018
Kursziel: AUD 31,70
Kursziel auf Sicht von: 12 Monate
Letzte Ratingänderung: -
Analyst: Peter Hasler

The light protection enabler

We're initiating coverage of Australian Clinuvel with a buy rating and a
price target of AUD 31.70 per share, since we believe investors are not
fully factoring in potential opportunities to Clinuvel's long-term growth
in the global skin protection market. The orphan disease drug company is
dramatically expanding top-line growth in the near-term as we expect the
company to expand its global footprint in EPP. Apart from these significant
growth opportunities, that even a rare disease like EPP offers, we expect
even more in the years to come, since (1) Clinuvel is expected to launch
its vitiligo product in 2021e, representing a substantial larger market
than the rare disease EPP, (2) the launch of a topical product should make
room for the mass market of non-prescription skin care solutions, and (3)
Clinuvel could also offer a treatment for various Central Nervous System
disorders among them MS, dementia, Alzheimer's, Parkinson's, ALS, or
Huntington's. Apart from EPP, none of these growth opportunities have so
far been factored in into our company valuation, leaving substantial upside
to our price target in the long-term.

Die vollständige Analyse können Sie hier downloaden:

Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
+49 (89) 74443558/ +49 (152) 31764553

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.